Hallucinogenic agents have been proposed as potent antidepressants; this includes the serotonin (5-HT) 27 receptor 2A agonist psilocybin. In human subjects, psilocybin alters functional connectivity (FC) within the 28 default-mode network (DMN), a constellation of inter-connected regions that is involved in self-reference 29 and displays altered FC in depressive disorders. In this study we investigated the effects of psilocybin on 30 FC in the analogue of the DMN in mouse, with a view to establishing an experimental animal model to 31 investigate underlying mechanisms. Psilocybin effects were investigated in lightly-anaesthetized mice using 32 resting-state fMRI. Dual-regression analysis identified reduced FC within the ventral striatum in psilocybin-33 relative to vehicle-treated mice. Refinement of the analysis using spatial references derived from both gene 34 expression maps and viral tracer projection fields revealed two distinct effects of psilocybin: it increased FC 35 between 5-HT-associated networks and elements of the murine DMN, thalamus, and midbrain; it decreased 36 FC within dopamine (DA)-associated striatal networks. These results suggest that interaction between 5-37 HT-and DA-regulated neural networks contributes to the neural and therefore psychological effects of 38 psilocybin. Furthermore, they highlight how information on molecular expression patterns and structural 39 connectivity can assist in the interpretation of pharmaco-fMRI findings.
Introduction

41
Psychiatric disorders are associated with changes in the status of specific neurotransmitter systems, 42 including those of serotonin (5-hydroxytryptamine, 5-HT) and dopamine (DA). Recently, psilocybin, a 43 psychedelic compound derived from "magic mushrooms" with high affinity to the 5-HTA receptor (Nichols, 44 2004; Halberstadt and Geyer, 2011) , has gained in research interest due to its potential to alleviate 45 depression and anxiety (Grob et al., 2011; Griffiths et al., 2016; Carhart-Harris et al., 2017a) . Whilst the 46 primary target of its active metabolite psilocin is the 5-HT2A receptor and it binds to a lesser extent to 47 receptor 5-HT1A , psilocybin has also been shown to induce DA release in the nucleus accumbens in rats 48 (Sakashita et al., 2015) and to reduce 11 C-raclopride binding to the D2 receptor in the caudate-putamen in 49 humans (Vollenweider et al., 1999) .
50
The direct and indirect actions of psilocybin on specific monoamine neurotransmitter systems result in 51 downstream metabolic and physiological effects on the brain. Thus, psilocybin increases global energy 52 metabolism indicated by elevated glucose utilization rates in the frontomedial, frontolateral and anterior 53 cingulate cortices as well as in basal ganglia (Vollenweider et al., 1997) . Also, somewhat counterintuitively, 
78
To test these hypotheses, we acquired resting-state fMRI data from mice treated with psilocybin or vehicle.
79
Conventional data analysis did not reveal any drug-induced alterations within elements of the rodent DMN.
80
Rather, we observed a significant decrease in striatal FC, pronounced in the ventral striatum, following 81 psilocybin. Gene expression maps for the 5-HT2A receptor or the D2 receptor, and axonal projection field 82 maps for dorsal raphe nucleus (DRN) 5-HT neurons and ventral tegmental area (VTA) DA neurons, were 83 used as spatial references for identifying 5-HT and DA contributions to the RSN changes induced by 84 psilocybin. This novel iterative approach revealed psilocybin effects not evident from conventional fMRI 85 analysis, and demonstrated that psilocybin does act on FC within the rodent DMN, albeit to a lesser extent 86 compared to its FC effects in the ventral striatum. These findings provide new translational insights into the 87 neuropharmacology of psilocybin.
89
Material and methods
90
Animal preparation and psilocybin administration 91 This study was conducted in accordance with federal guidelines and under a license from the Zürich 92 Cantonal Veterinary Office (149/2015). A total of 50 young-adult male C57BL/6 mice (Janvier, Le Genest-93 St Isle, France) weighing 25 ± 1.2 g were studied. Animals were maintained in standard housing with food 94 and water available ad libitum and in a reversed 12:12 day/night cycle (light off: 07:00-19:00 h). Anaesthesia 95 was induced with isoflurane 3.5% in a mixture of 20% O2 and 80% air. Isoflurane was reduced to 2%, 96 animals were then intubated endotracheally and ventilated mechanically at 80 breaths/min, positioned on 97 an MR-compatible cradle, and a cannula was positioned in the tail vein. Psilocybin was dissolved in sterile 98 water with tartaric acid and infused i.v. during 5 min with either 1 mg/kg (n = 13) or 2 mg/kg (n = 12) or 99 vehicle only (n = 15). These doses were chosen because they were demonstrated previously to elicit RSNs there was no significant dose-dependent psilocybin effect, and therefore the two dose groups were 197 pooled to enhance statistical power and the analysis run again. The psilocybin effect of reduced FC in the 198 ventral striatum was robust and reproducible, as the two subsets revealed similar results ( Figure S1 ).
199
Psilocybin effects on FC were obtained within three additional RSNs, the piriform cortex, dorsal striatum 200 and lateral striatum ( Figure S2) ; however, these effects did not survive the second stage of statistical 201 correction, namely Bonferroni threshold. In a network analysis, there were no significant psilocybin effects 202 on between-network FCs for any pair of RSNs after full correction. We conclude that the striatal networks, 203 and in particular the ventral striatum RSN, were the most responsive to psilocybin, therefore. 
276
To differentiate the effects of psilocybin on 5-HT-and DA-associated networks across the whole brain, a 277 dual-regression analysis was carried with brain-wide Drd2 and Htr2a gene expressions used as spatial 278 reference maps (Figure 4a and b, Figure S3a ). The averaged resting BOLD time series from the regions 279 delineated in these reference maps were extracted and used to establish FC between these reference 280 regions and the remaining voxels across the whole-brain. The dual-regression analysis revealed reduced 281 FC between the Drd2 expressing regions and the striatum, pallidum and thalamus in psilocybin versus 12 vehicle-treated mice, comparable to the results obtained previously (Figure 1) . A weak opposite effect, i.e. 283 increased FC due to psilocybin, was found between Htr2a expressing regions and the left dorsal striatum, 284 although this effect did not survive statistical correction in the subsequent ROI analysis (Figure 4b ).
285
Analyses carried out for other 5-HT receptor gene-expression maps did not reveal significant clusters. To 286 confirm these results, we used viral tracer maps, obtained by virus injection targeting DA neurons in the 287 VTA or 5-HT neurons in the DRN, as spatial references in the dual-regression analysis (Figure 4c and d, 288 Figure S3b ). In agreement with the results based on gene expression levels, psilocybin induced a significant 289 decrease in FC between the VTA projection fields and the medial and posterior subfields of the striatum. In 290 contrast, psilocybin administration increased FC between the DRN projection fields and the dorsal striatum, 291 retrosplenial cortex, visual cortex, thalamus and midbrain. We conclude that psilocybin administration 292 exerts differential effects on 5-HT-and DA-associated networks; namely, it increases FC between the 5-
293
HT system and several striatal, cortical, and thalamic regions, and decreases FC between the DA system 294 and striatal regions. It is noteworthy that the 5-HT-related effects were not detected when applying 
328
Reference spatial maps used to delineate Drd2-and Htr2a-expressing regions, as well as VTA and DRN projections 329 are indicated in Figure S3 .
331
The DMN is considered to be one of the most important systems underlying higher cognitive functions 332 (Raichle et al., 2001) , and within-and between-region FC is increased in depression (Sheline et al., 2010) 333 and animal models thereof (Grandjean et al., 2016) . In human volunteers receiving either psilocybin or 
381
We are aware of potential limitations associated with our approach. Firstly, psilocin administration has been 382 associated with decoupling between the hemodynamic response and neuronal activity in rats during short-383 duration, high frequency (>10 Hz) whisker sensory stimulation (Spain et al., 2015) ; however, this was not 384 the case for lower frequency paradigms. Moreover, this effect would not be expected to be confined to 385 specific RSNs, hence the relevance of this observation in the context of resting-state FC remains moot.
386
Second, database resources of gene expression or viral tracer maps differ in map coverage and quality.
387
Image artefact or misregistration could impact the analysis when used as priors. For instance, only a subset 388 of the 5-HT gene expression maps available on the AIBS database met our quality assurance criterion, 389 restricting the scope of our analysis to this subset of 5-HT genes. Finally, we have used a relatively high 390 dose of psilocybin compared to studies in humans (Carhart-Harris et al., 2012). Species-specific 391 pharmacokinetic and pharmacodynamic properties may account for the large difference in drug dose 392 required to elicit pharmacological responses in humans and rodents.
394
In conclusion, we have demonstrated robust effects of psilocybin on FC within the striatal RSNs.
395
Incorporation of neurotransmitter-specific gene expression and viral tracer maps into our analysis enabled 396 further refinement. In particular, we found differential psilocybin effects in 5-HT versus DA associated 
